HSS Appoints Christopher Dunleavy as Chief Financial Officer
Former CFO at Brigham, Baylor, USMD will succeed
Dunleavy has previously served as CFO at larger healthcare provider systems including
"Chris was the consensus recommendation of the search committee following a process that identified five exceptional and diverse finalists," said HSS president and chief executive officer
Kelly said the process also revealed further strength in the HSS Finance leadership team. "I'm confident Chris will enable a springboard for our exceptional leaders to realize their potential, at an important moment of opportunity for our organization. Stacey will leave big shoes to fill, and we have tremendous opportunities to navigate."
The HSS search committee of 28 comprised physicians, executives and Board members.
"I cannot imagine a greater opportunity for me to impact on the field of medicine," said Dunleavy. "With world-renowned quality and a strong balance sheet, the Finance function can and will enable HSS – the world's largest concentration of expertise in musculoskeletal health – to rise to new opportunities in the changing healthcare landscape."
"I look forward to partnering with my new world-class team-mates to build on Stacey's legacy and newly empower the organization's next generation of success."
HSS Surgeon-in-Chief and Medical Director
About HSS
HSS is the world's leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the 15th consecutive year), No. 3 in rheumatology by U.S. News & World Report (2024-2025), and the best pediatric orthopedic hospital in NY, NJ and CT by
View original content to download multimedia:https://www.prnewswire.com/news-releases/hss-appoints-christopher-dunleavy-as-chief-financial-officer-302319764.html
SOURCE Hospital for Special Surgery
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GIM Raises US$20 Million Series A as Agentic Investing Enters Live Execution
- "Search, Not Discounts, Decided Amazon Prime Day 2026's Beauty Winners: Market Defense Report"
- Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share